Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year

Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year
The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals' investigational therapy AMX0035 in people with Alzheimer's disease. Top-line results from the trial are expected in the first half of 2021. "The PEGASUS trial design and broad inclusion criteria will allow us to assess whether AMX0035 can prevent neurodegeneration in people with Alzheimer’s via MR imaging and fluid biomarkers," Steven E. Arnold, MD, trial principal investigator, and professor at Massachusetts General Hospital and Harvard Medical School, said in a press release. "We are immensely thankful to the trial participants and their families for their time and commitment to this critical research effort," he said. AMX0035 is an oral formulation of sodium phenylbutyrate (PB) and tauroursodeoxycholic-acid (TUDCA). PB helps stop proteins from unfolding — protein unfolding is associated with the toxic accumulation of proteins in nerve cells. TUDCA helps to limit the loss of cellular energy, which is involved in the progression of neurological diseases like Alzheimer's. Amylyx 
Subscribe or to access all post and page content.